Vaxcyte, Inc. Stock Price, News & Analysis

Vaxcyte (Nasdaq: PCVX) announced the completion of an underwritten public offering of 17,812,500 shares of common stock at $32.00 per share, along with pre-funded warrants for 3,750,000 shares at $31.999 each. The offering raised approximately $690 million in gross proceeds. The transaction included the underwriters' full exercise of their option for an additional 2,812,500 shares. BofA Securities and others acted as joint book-running managers. Vaxcyte focuses on innovative vaccines to combat bacterial diseases, with its lead candidate VAX-24 targeting invasive pneumococcal disease.

Vaxcyte, Inc. (Nasdaq: PCVX) has priced an underwritten public offering of 15,000,000 shares of common stock and pre-funded warrants to purchase 3,750,000 shares at $32.00 and $31.999 per share, respectively. The offering aims to raise approximately $600 million, closing on October 28, 2022, subject to customary conditions. Vaxcyte’s lead vaccine candidate, VAX-24, targets invasive pneumococcal diseases, while its innovative protein synthesis methods enhance vaccine production. The underwriters have a 30-day option to purchase an additional 2,812,500 shares.

Vaxcyte, Inc. (Nasdaq: PCVX) has initiated an underwritten public offering of common stock and pre-funded warrants. The company plans to grant underwriters a 30-day option to acquire an additional 15% of offered shares. The offering's completion is contingent on market conditions. BofA Securities, Jefferies, SVB Securities, Evercore ISI, and Guggenheim Securities are the main managers for this offering. A shelf registration statement was filed with the SEC, and a preliminary prospectus will be available. No offers are to be made in jurisdictions where unlawful.

Vaxcyte announced positive topline results from its Phase 1/2 clinical study of VAX-24, a 24-valent pneumococcal conjugate vaccine, demonstrating a strong safety and tolerability profile similar to Prevnar 20 (PCV20). At the 2.2mcg dose, VAX-24 met or exceeded regulatory immunogenicity standards for all 24 serotypes and showed higher immune responses for 16 of the 20 serotypes common with PCV20. Vaxcyte intends to advance VAX-24 into a Phase 3 program.

The FDA granted Fast Track Designation to VAX-24 for the adult indication, underscoring its potential in preventing invasive pneumococcal disease.

Vaxcyte, Inc. (Nasdaq: PCVX) announced a webcast on October 24, 2022, at 8:00 a.m. Eastern Time to discuss topline results from its Phase 1/2 proof-of-concept study for VAX-24, a 24-valent pneumococcal conjugate vaccine. The study evaluates safety, tolerability, and immunogenicity in healthy adults aged 18-64. Vaxcyte aims to innovate vaccine development using the XpressCF™ platform, striving to combat invasive bacterial infections with high-fidelity vaccines. The results will inform next steps for VAX-24 and Vaxcyte's broader vaccine portfolio.

Vaxcyte, Inc. (Nasdaq: PCVX) has announced the appointments of Mark Wiggins as Chief Business Officer and Jakub Simon as Chief Medical Officer to enhance its management team. With extensive experience in the biopharmaceutical sector, both leaders aim to drive the company’s growth and advance its lead vaccine candidate, VAX-24, a 24-valent pneumococcal conjugate vaccine. Vaxcyte anticipates announcing topline results from VAX-24's proof-of-concept study by late 2022, positioning the company for significant progress in vaccine development.

Vaxcyte, Inc. (Nasdaq: PCVX) has completed enrollment for its Phase 2 study of VAX-24, a 24-valent pneumococcal conjugate vaccine, targeting adults aged 65 and older. This study aims to assess the safety, tolerability, and immunogenicity of the vaccine, crucial for preventing invasive pneumococcal disease (IPD). Approximately 200 participants are involved, with topline results expected in H1 2023. VAX-24 has received Fast Track designation from the FDA, highlighting its potential to meet unmet medical needs in preventing pneumococcal disease, particularly in older adults.

Vaxcyte, Inc. (Nasdaq: PCVX), reported a successful enrollment of the Phase 2 study for its 24-valent pneumococcal conjugate vaccine, VAX-24, in adults. Topline results are expected by late 2022. The company received FDA Fast Track designation for VAX-24, facilitating quicker clinical progression. Financially, Vaxcyte's cash reserves stood at $361.4 million as of June 30, 2022, with increased R&D expenses totaling $38.5 million, leading to a net loss of $48.5 million for the quarter.

Vaxcyte (Nasdaq: PCVX) announced that its 24-valent pneumococcal conjugate vaccine, VAX-24, received Fast Track designation from the FDA for adults aged 18 and older. This designation aims to expedite the vaccine's development and review due to its potential to address an unmet medical need. Additionally, following a successful pre-IND meeting, the company obtained positive feedback for initiating a pediatric study targeting infants, contingent on results from ongoing adult trials. VAX-24 aims to enhance protection against invasive pneumococcal disease, particularly in vulnerable populations.